Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.

The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Netherlands Cancer Institute
• Collaborator: Hoffmann-La Roche
• Treatments: Antibodies, Monoclonal; Atezolizumab; Capecitabine; Docetaxel; Oxaliplatin

Criteria

Inclusion Criteria:

• signed informed consent

• patients age 18 and older

• primary resectable, histologically confirmed gastric or GEJ adenocarcinoma

Exclusion Criteria:

• no signs of distant metastases

• no active or history of autoimmune disease or immune deficiency

• no significant cardiovascular disease

• no major surgical procedure within 4 weeks prior to initiation of study treatment

• no current treatment with anti-viral therapy or HBV

• no pregnancy or breastfeeding

• no history of malignancy within 3 years prior to screening